Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Rilematovir Concept Formulations in Healthy Adults
NCT02945007Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rilematovir in respiratory syncytial virus infection (RSV) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration and 3 more. Started Nov 2016; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02945007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945007.